Intensity Modulated Radiotherapy in Recurrent T1-2 Nasopharyngeal Carcinoma

Not Applicable

Completed

• Conditions: Nasopharyngeal Cancer Recurrent
• Interventions: Radiation: 3D-CRT, IMRT, BT, BT combined 3D-CRT or IMRT

• Registration Number: NCT02113423
• Lead Sponsor: Fujian Cancer Hospital

Brief Summary

The hypothesis of the study is to address the efficacy and toxicity profile of aforementioned four modalities for rT1-2 NPC.

Characters of the patients:

* list item one: 168 patients, median age 48 years (range 16-75 years） proven rT1-2 NPC were diagnosed

* list item two: Treated with four different irradiation modalities(3D-CRT,IMRT, BT , BT Combined 3D-CRT or IMRT).

* list item three: Median time to recurrence was 30 months (range 1-180months). The median follow-up time was 28 months (range, 4-135 months).

Detailed Description

Objectives:

Recurrent T1-2 Nasopharyngeal Carcinoma (rT1-2) may be salvaged by 3D - CRT（3D-Conformal Radiotherapy）, IMRT（ Intensity Modulated Radiotherapy）, Brachytherapy (BT), BT combined 3D - CRT or IMRT . The aim of this study is to address the efficacy and toxicity profile of aforementioned four modalities for rT1-2 NPC.

Methods and Materials:

168 patients, median age 48 years (range 16-75 years） proven rT1-2 NPC were diagnosed and treated with four different irradiation modalities(3D-CRT,IMRT, BT , BT Combined 3D-CRT or IMRT) . Median time to recurrence was 30 months (range 1-180months). The median follow-up time was 28 months (range, 4-135 months).

Study Timeline

• Study Start: 1996-01
• Primary Completion: 2009-06
• Study Completion: 2011-03
• Status Verified: 2014-04
• Study First Submitted: 2014-04-08
• Study First Submitted QC: 2014-04-10
• Last Update Submitted: 2014-04-10
• Study First Posted: 2014-04-14
• Last Update Posted: 2014-04-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 168

Inclusion Criteria

• recurrent T1-2 nasopharyngeal carcinoma patients

Read More

Exclusion Criteria

• non recurrent T1-2 nasopharyngeal carcinoma patients

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
recurrent T1-2 NPC,no treatment	3D-CRT, IMRT, BT, BT combined 3D-CRT or IMRT	3D-CRT, IMRT, BT, BT combined 3D-CRT or IMRT

Primary Outcome Measures

Name	Time	Method
all cause mortality	thirteen years

Trial Locations

Locations (1)

Fujian Cancer Hospital Radiation Oncology Department; 🇨🇳 Fuzhou, Fujian, China